These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 30681655)

  • 1. Fremanezumab (Ajovy) and galcanezumab (Emgality) for migraine prevention.
    Med Lett Drugs Ther; 2018 Nov; 60(1559):177-180. PubMed ID: 30681655
    [No Abstract]   [Full Text] [Related]  

  • 2. Erenumab (Aimovig) for migraine prevention.
    Med Lett Drugs Ther; 2018 Jun; 60(1549):101-103. PubMed ID: 29913472
    [No Abstract]   [Full Text] [Related]  

  • 3. Eptinezumab (Vyepti) for migraine prevention.
    Med Lett Drugs Ther; 2020 Jun; 62(1599):85-87. PubMed ID: 32555116
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison table: Some drugs for migraine prevention in adults.
    Med Lett Drugs Ther; 2023 Jun; 65(1678):e100-e102. PubMed ID: 37266989
    [No Abstract]   [Full Text] [Related]  

  • 5. Atogepant (Qulipta) for migraine prevention.
    Med Lett Drugs Ther; 2021 Nov; 63(1636):169-171. PubMed ID: 35085204
    [No Abstract]   [Full Text] [Related]  

  • 6. Drugs for migraine.
    Med Lett Drugs Ther; 2023 Jun; 65(1678):89-96. PubMed ID: 37266987
    [No Abstract]   [Full Text] [Related]  

  • 7. Drugs for Migraine.
    Med Lett Drugs Ther; 2020 Oct; 62(1608):153-160. PubMed ID: 33434187
    [No Abstract]   [Full Text] [Related]  

  • 8. In brief: Erenumab (Aimovig) hypersensitivity.
    Med Lett Drugs Ther; 2019 Mar; 61(1568):48. PubMed ID: 31022159
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials.
    Xu D; Chen D; Zhu LN; Tan G; Wang HJ; Zhang Y; Liu L
    Cephalalgia; 2019 Aug; 39(9):1164-1179. PubMed ID: 30789292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis.
    Drellia K; Kokoti L; Deligianni CI; Papadopoulos D; Mitsikostas DD
    Cephalalgia; 2021 Jun; 41(7):851-864. PubMed ID: 33567891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines.
    Cohen JM; Dodick DW; Yang R; Newman LC; Li T; Aycardi E; Bigal ME
    Headache; 2017 Oct; 57(9):1375-1384. PubMed ID: 28862758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zavegepant (Zavzpret) for acute treatment of migraine.
    Med Lett Drugs Ther; 2023 Jul; 65(1681):116-118. PubMed ID: 37460143
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost of fremanezumab, erenumab, galcanezumab and onabotulinumtoxinA associated adverse events, for migraine prophylaxis in Spain.
    Irimia P; Santos-Lasaosa S; García Bujalance L; Ramos Pinazo L; Rubio-Rodríguez D; Rubio-Terrés C
    Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):285-297. PubMed ID: 32484365
    [No Abstract]   [Full Text] [Related]  

  • 14. Rimegepant (Nurtec ODT) for acute treatment of migraine.
    Med Lett Drugs Ther; 2020 May; 62(1597):70-72. PubMed ID: 32555113
    [No Abstract]   [Full Text] [Related]  

  • 15. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.
    Sacco S; Bendtsen L; Ashina M; Reuter U; Terwindt G; Mitsikostas DD; Martelletti P
    J Headache Pain; 2019 Jan; 20(1):6. PubMed ID: 30651064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CGRP Pathway in Migraine as a Viable Target for Therapies.
    Edvinsson L
    Headache; 2018 May; 58 Suppl 1():33-47. PubMed ID: 29697153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.
    Dodick DW; Silberstein SD; Bigal ME; Yeung PP; Goadsby PJ; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y; Aycardi E
    JAMA; 2018 May; 319(19):1999-2008. PubMed ID: 29800211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial.
    Skljarevski V; Matharu M; Millen BA; Ossipov MH; Kim BK; Yang JY
    Cephalalgia; 2018 Jul; 38(8):1442-1454. PubMed ID: 29848108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class.
    Arca K; Reynolds J; Sands KA; Shiue HJ
    Ann Pharmacother; 2020 Aug; 54(8):795-803. PubMed ID: 32019317
    [No Abstract]   [Full Text] [Related]  

  • 20. A comprehensive overview and safety evaluation of fremanezumab as a preventive therapy for migraine.
    Parikh SK; Burkett JG; Silberstein SD
    Expert Opin Drug Saf; 2020 May; 19(5):537-543. PubMed ID: 32116061
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.